Tiglilo double antiplatelet therapy for patients with acute coronary syndrome after PCI

Objective To evaluate the effect of tiglilo double antiplatelet therapy after percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS). Methods 110 patients with ACS who were admitted to our hospital from January, 2017 to October, 2018 for PCI were divided into two a control group and a study group, 55 cases for each group. The control group received aspirin plus clopidogrel antiplatelet therapy after operation, and the study group was treated with aspirin and tegrillo. The platelet function, inflammatory indicators, and platelet inhibition were observed. Results After the treatment, the levels of sCD40L, MPAR, and PRU, as well as the levels of hs-CRP, ET-1, and MMP-9, were significantly lower and the level of NO was significantly higher in the study group than in the control group (all P 0.05). Conclusion Tiglilo double antiplatelet therapy after PCI for patients with ACS can effectively improve the platelet aggregation and platelet inhibition rate and significantly reduce the inflammatory reaction in blood vessels, which is helpful to reduce the risk of adverse cardiac events after operation. Key words: Acute coronary syndrome; Percutaneous coronary intervention; Aspirin; Tigrillo; Antiplatelet